Non-invasive Prenatal Testing (NIPT) Market to Grow with a CAGR of 7.42% through 2030
Growing
incidence of chromosomal abnormalities and availability of advanced screening
technologies, is expected to drive the Global Non-invasive Prenatal Testing (NIPT) Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Non-invasive Prenatal Testing (NIPT) Market –
Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030F”, the Global Non-invasive Prenatal Testing (NIPT)
Market stood at USD 5.03
Billion in 2024 and is expected to reach USD 7.74 Billion by
2030 with a CAGR of 7.42% during the forecast period. The increasing
prevalence of genetic disorders in fetuses is a significant driver for market
growth. Moreover, advancements in technology within the life sciences and
healthcare industries are providing a substantial boost to the market. For
example, the development of DNA sequencing technologies, breakthroughs in
molecular research, and regenerative medicines have opened up immense
possibilities for early detection and prevention of serious diseases.
Additionally, the growing acceptance rate of prenatal testing, coupled with
increased health consciousness and awareness among the general population, is
driving market growth. Healthcare providers and expecting parents are
increasingly turning to alternative diagnostics for genetic disorders such as
spina bifida, cleft palate, and sickle cell anemia, enabling early intervention
during fetal development. Furthermore, the trend of childbearing at a higher
maternal age (35 years or older) is also positively influencing market growth,
despite the associated health complications including high blood pressure,
reduced fertility, and increased risk of chromosomal anomalies in the fetus.
The
demand for Non-Invasive Prenatal Testing (NIPT) is rising in various countries
due to several factors. These include an increasing number of doctors opting
for advanced genetic testing for high-risk pregnancies, a desire to postpone
pregnancy, and a rise in pregnancy-related complications during the second or
third trimester. Traditional invasive prenatal testing methods like chorionic
villus sampling and amniocentesis can lead to complications such as
miscarriage. Consequently, there has been a decline in the utilization of these
procedures and a surge in demand for more efficient, noninvasive, and safe
tests. NIPT utilizes cell-free fetal DNA (cffDNA) present in the mother's blood
to detect common trisomies such as Turner syndrome, Down syndrome, fetal rhesus
D status, sex chromosome disorders, and determine fetal sex. The market for
NIPT is highly competitive, with numerous key players operating in the field.
To maintain a stronghold in the market, companies are forming strategic
partnerships and collaborations. For example, in June 2021, Illumina
collaborated with Next Generation Genomic to introduce VeriSeq NIPT Solution
v2, a CE-IVD, NGS-based NIPT test in Thailand. This collaboration aims to
enhance patient access to next-generation sequencing-based NIPT. The market is
driven by constant improvements and advancements in existing products. Notably,
in April 2020, Natera expanded the coverage of its product Panorama to cater to
all pregnant women regardless of age or conditions. The introduction of innovative
products is expected to have a positive impact on the market. Moreover,
increased reimbursement coverage for newly introduced products is anticipated
to further boost product adoption.
The age of a woman at the time of delivery is commonly referred to as her maternal age. Advancing maternal age can result in various health complications, including decreased fertility, hypertension, and an elevated risk of miscarriage, stillbirths, and maternal mortality. Additionally, due to errors in chromosomal division, maternal age can contribute to a higher incidence of genetic abnormalities in newborns. Neonates may exhibit conditions such as microcephaly, a shortened neck, upward slanted eyes, weak muscle tone, and complications related to the heart, intestines, and respiration. These findings suggest a global increase in maternal advanced age, which is likely to result in more health challenges. Consequently, the rising maternal age, coupled with the growing prevalence of chromosomal abnormalities, is anticipated to drive the demand for non-invasive prenatal testing (NIPT). The increasing occurrence of chromosomal abnormalities, along with expanded applications of NIPT, are key drivers of organic revenue growth in the market. Moreover, advancements in existing tests, encompassing enhanced functionality, improved chemistry, and bioinformatics analysis, are projected to fuel market expansion. The enhancement of payment policies for routine and low-risk pregnancies serves as a primary catalyst for market growth.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"Global Non-invasive Prenatal Testing (NIPT) Market”
The
Global Non-invasive Prenatal Testing (NIPT) Market is segmented into product
type, test type, method, application, end user, regional distribution, and
company.
Based on the Application,
Trisomy emerged as the fastest growing segment in the Global Non-invasive
Prenatal Testing (NIPT) Market during the forecast period. Trisomy, a genetic
condition caused by an extra chromosome, includes disorders such as Down
syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome
(trisomy 13). NIPT is increasingly being used to screen for these conditions
due to its high accuracy and non-invasive nature, making it a preferred choice
for expectant mothers. The growing demand for trisomy screening can be
attributed to the rising awareness of genetic conditions and the importance of
early detection. With NIPT offering a safer and more accurate alternative to
traditional invasive tests, such as amniocentesis, expectant parents are more
inclined to opt for this non-invasive screening method. As healthcare systems
across Europe integrate NIPT into standard prenatal care, trisomy screening has
become a key focus.
Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global Non-invasive Prenatal Testing (NIPT) Market during the forecast period. The favorable regulatory developments and investments in biotechnology are accelerating market growth across the region. Governments are supporting innovation in genomics and genetic testing through public-private partnerships and funding research institutions. Local companies are expanding their footprint by collaborating with global players, facilitating the transfer of technical know-how and improving the affordability of NIPT solutions. Advancements in laboratory automation and data analytics are enabling faster, more accurate results, while local manufacturers are focusing on cost-effective test kits tailored to regional genetic profiles. The growing focus on maternal and fetal health in rural and semi-urban areas, combined with the increasing presence of mobile diagnostics and telemedicine platforms, is further strengthening NIPT adoption across Asia-Pacific. These developments collectively underscore the region’s dynamic growth potential and its evolving role in shaping the future of prenatal diagnostics.
Major companies operating in Global Non-invasive Prenatal
Testing (NIPT) Market are:
- YOURGENE HEALTH Plc
- Illumina, Inc.
- Natera, Inc.
- Hoffman La Roche Ltd.
- Perkin Elmer Inc.
- Laboratory Corporation of America
Holdings
- Eurofins LifeCodex GmbH
- Progenity, Inc.
- Genesis Genetics
- Quest Diagnostics Incorporated
Download Free Sample Report
Customers can also request for 10% free customization on
this report
“NIPT
has the potential to be incorporated into routine antenatal care, as indicated
by numerous healthcare specialists. Non-invasive prenatal testing is gaining
popularity among pregnant women as a safer alternative to amniocentesis,
especially as awareness of prenatal genetic concerns grows. Due to the higher
rates of miscarriage and complications, non-invasive prenatal testing is
expected to become the standard procedure in the future, replacing previous,
riskier screening methods. With a detection accuracy above 99 percent and a
shorter screening time compared to other prenatal screening methods, NIPT
stands out. Limited companies currently offer non-invasive prenatal testing.
The market's growth is driven by the higher risk of chromosomal abnormalities
with increasing maternal age, the rising incidence of chromosomal aneuploidies
among fetuses, the development of advanced non-invasive prenatal testing
products, and improvements in reimbursement. Moreover, the increasing awareness
of non-invasive prenatal testing and untapped market potential in emerging
nations in Asia provide significant revenue growth opportunities for market
participants. The growing preference for non-invasive techniques over invasive
methods is also attracting market expansion.,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Non-invasive Prenatal
Testing (NIPT) Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Product Type (Consumables, Instruments), By Test Type
(Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Method (Ultrasound
Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests,
Fetal Cells in Maternal Blood Tests, Others), By Application (Trisomy,
Microdeletion Syndrome, Others), By End User (Diagnostic Laboratories,
Hospitals, Others), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Non-invasive Prenatal
Testing (NIPT) Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Non-invasive
Prenatal Testing (NIPT) Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com